Evaluation and management of patients with heart disease and cancer: cardio-oncology
about
Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference?Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer TherapyCardiovascular Disease in Women: Clinical Perspectives.Cardio-oncology: what you need to know now for clinical practice and echocardiography.Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study.Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway.Incidence and trends of cardiovascular mortality after common cancers in young adults: Analysis of surveillance, epidemiology and end-results programBenefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.Cardio-oncology: an ongoing evolution.Systems biology approaches to adverse drug effects: the example of cardio-oncology.Cardio-oncology: cardiovascular complications of cancer therapy.Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.Cardiotoxicity from the cardiologist's perspective.Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool?Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy.Cardio-oncology.Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma.Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.Should vascular effects of newer treatments be addressed more completely?Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis.Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013.Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.Radiation-Induced Cardiovascular Disease: Mechanisms and Importance of Linear Energy Transfer.Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.[Current recommendations for diagnostic echocardiography in cancer patients : Is echocardiography too late or too early?]Lung cancer as a cardiotoxic state: a review."Cardio-Oncology": Implications for interventionists.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesTowards evidence-based management of patients treated with cardiotoxic chemotherapy: A collaborative effort of cardiologists and oncologistsCardio-oncology: A Focus on CardiotoxicityGuest Editorial: Is Cardio-oncology Ready for Algorithms?Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction
P2860
Q26740352-EED14D42-9FC4-411A-B189-09073F1646DBQ26797138-AC1F1719-CEC1-4A7F-BE80-4FDCD170D59DQ30743765-D05627CC-A806-4F71-9D7D-00B29DFC725CQ33701308-9B70CAE4-EB0F-4BA0-8E19-BE379B6070B3Q35957861-13EF1C87-5594-4362-9C96-08436C3ECCFAQ36163330-8F5E72EF-1435-4E4F-8422-52E01D988F35Q36451899-D46330D4-06A3-465B-BA0F-5BC1D1EF3CD5Q36551901-1FD0E263-43B8-4E4C-879A-1F7FD8353185Q36601680-E058C6BD-20FA-4902-92B8-C445BC78C584Q37035108-4BA0A211-177C-498E-A55C-AD6CA4B09916Q37311943-ACC5AF9D-3970-4BCC-9DD6-033F1A23ED41Q38551766-A9822B18-E245-4345-BD9B-1F10A8E88B98Q38606067-DF6DE092-FAB3-4A40-9E38-128FAFD1F500Q38665281-60865E8F-D8E5-425F-BA1F-5588D2A660DFQ38938410-5E4CD873-07C9-4A63-805F-9B1B7AFFA47FQ38978582-562EB5E9-1851-465D-85CA-C30299E81489Q38982319-4C4C8B34-59BB-4B2E-9748-E10F4DD882E4Q39018351-287522F6-4CFC-4DF0-B8E5-43CD6EB2BF0CQ39076609-731EB862-7AB8-4E40-96FE-4D62CE75919BQ39962402-7FFA3DE1-25CF-4685-A7AC-26AF97EBB42CQ40500474-DB587859-A3F2-44A1-805A-76643A5CA411Q41288150-BCDBFBC5-8B46-4E79-9323-362FB9204642Q44242155-35BB3B21-B824-495F-984D-1AEAFE23504EQ45073135-4365F1A7-41D4-453C-8380-DADB03F18B90Q47155288-AF0C5DD5-11D4-4D45-8C18-71E9359AA461Q47610317-12A7E32A-2B1C-4953-9CB6-1401A57BAF7DQ48168034-4949EF0D-4FA9-4485-A8DB-714F6A0890A5Q48635788-447E2FD0-9E93-408D-8040-B2E81B8B8A9DQ49287618-0DB48BF4-DA4A-45CD-8A5C-1C245045BDCAQ50079226-074C8D7D-FDDD-4BC2-8AA4-44FD3818596BQ50418924-79D13B32-1518-4FB2-8349-F3062917B962Q53117997-4B2DD0DC-5EDC-44F3-A3D9-6F0249D63897Q54139999-3334B5DB-D7F7-4063-92DA-681A0BCCC5C6Q57057499-9AA2A761-AF0C-40B2-A98D-5072FA8EBD0FQ57060411-51F2381E-58FF-4975-B006-E75BB01AD6B4Q57495835-6773FA29-4701-406D-8296-AA39231B9FDAQ57495837-03544EF1-77EA-4141-9478-6234816BA007Q58130037-4D27EB37-6191-403D-B197-D66BF02962E8
P2860
Evaluation and management of patients with heart disease and cancer: cardio-oncology
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@ast
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@en
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@nl
type
label
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@ast
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@en
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@nl
prefLabel
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@ast
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@en
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@nl
P2093
P2860
P3181
P1476
Evaluation and management of patients with heart disease and cancer: cardio-oncology
@en
P2093
Hector R. Villarraga
Joerg Herrmann
Manish Kohli
Nicole P. Sandhu
Sharon L. Mulvagh
P2860
P304
P3181
P356
10.1016/J.MAYOCP.2014.05.013
P407
P50
P577
2014-09-01T00:00:00Z